FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds of formula I, where the values A, B, C, L, R2, R3, R7-R9, m, p are specified in the claims, which are selective allosteric inhibitors of EGFR mutant variants containing T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S and to pharmaceutical compositions containing these compounds.
EFFECT: compounds can be used in the preparation of an agent for the therapeutic and/or prophylactic treatment of non-small cell lung cancer characterized by mutations activating EGFR.
15 cl, 8 tbl, 68 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS | 2018 |
|
RU2774952C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| BICYCLIC KETONES AND METHODS OF THEIR USE | 2018 |
|
RU2797922C2 |
| SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR TREATING VESTIBULAR DISORDERS | 2009 |
|
RU2589846C2 |
| NOVEL (HETERO)ARYL-SUBSTITUTED PIPERIDINYL DERIVATIVES, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2017 |
|
RU2742271C2 |
| COMPOUNDS 6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE | 2017 |
|
RU2719599C2 |
| HEXONE-GLUCOKINASE INHIBITOR AND ITS USE | 2020 |
|
RU2797185C2 |
| HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | 2013 |
|
RU2671628C2 |
| EGFR INHIBITOR FOR TREATING CANCER | 2020 |
|
RU2818677C2 |
| SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | 2013 |
|
RU2666538C2 |
